Donate Help Contact The AHA Sign In Home
American Heart Association
Hypertension
Search: search_blue_button Advanced Search
Hypertension. 2008;52:1084-1090
Published online before print November 3, 2008, doi: 10.1161/HYPERTENSIONAHA.108.114298
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
52/6/1084    most recent
HYPERTENSIONAHA.108.114298v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Rajapakse, N. W.
Right arrow Articles by Mattson, D. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Rajapakse, N. W.
Right arrow Articles by Mattson, D. L.
Right arrowPubmed/NCBI databases
*Compound via MeSH
*Substance via MeSH
Hazardous Substances DB
*(L)-ARGININE
*NITRIC OXIDE
Related Collections
Right arrow Animal models of human disease
Right arrow Other hypertension
Right arrow Endothelium/vascular type/nitric oxide

(Hypertension. 2008;52:1084.)
© 2008 American Heart Association, Inc.


Original Articles

Exogenous L-Arginine Ameliorates Angiotensin II-Induced Hypertension and Renal Damage in Rats

Niwanthi W. Rajapakse; Carmen De Miguel; Satarupa Das; David L. Mattson

From the Department of Physiology, Medical College of Wisconsin, Milwaukee. Current address (N.W.R.): Department of Physiology, Monash University, Melbourne, Australia.

Correspondence to Niwanthi W. Rajapakse, Department of Physiology, PO Box 13F, Monash University, Melbourne 3800, Australia. E-mail niwanthi.rajapakse{at}med.monash.edu.au

Experiments were performed to determine whether exogenous L-arginine could ameliorate angiotensin II-induced hypertension and renal damage. Rats were instrumented with chronic indwelling femoral venous and arterial catheters for infusions of drugs and measurement of conscious arterial pressure. Arterial blood pressure significantly increased from 124±1 to 199±4 mm Hg, after 9 days of continuous infusion of angiotensin II (20 ng/kg per minute; IV; n=6 to 9). In contrast, the increase in arterial pressure after 9 days of angiotensin II infusion was significantly blunted by 45% (P=0.0003) in rats coadministered L-arginine (300 µg/kg per minute; IV; n=7 to 9). The glomerular injury index was significantly greater in rats administered angiotensin II in comparison with rats administered saline vehicle (P<0.001). Coinfusion of L-arginine significantly increased plasma nitrate/nitrite concentrations (P<0.001) and completely prevented angiotensin II-induced glomerular damage (P<0.001). Angiotensin II infusion alone and combined angiotensin II plus L-arginine infusion significantly increased urinary albumin excretion. Albuminuria in rats administered angiotensin II plus L-arginine is likely to be because of increased intraglomerular pressure. Our experiments demonstrate that L-arginine can blunt angiotensin II-induced hypertension and associated renal damage. This latter observation is most exciting because it indicates that increasing NO bioavailability, in addition to lowering arterial pressure, can greatly reduce hypertension-induced renal damage.


Key Words: hypertension • angiotensin II • L-arginine • NO • kidney